Schedule 13G ownership disclosure
ADAPTIMMUNE THERAPEUTICS PLC
Ordinary Shares, par value 0.001 GBP per share · CUSIP: 00653A107
Event date: 2024-11-30
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Matrix Capital Management Company LP
Shares: 135,000,000.00 · Class: 8.8%
- David E. Goel
Shares: 135,000,000.00 · Class: 8.8%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000902664-24-006837
- Form type
- SCHEDULE 13G/A
- Filer
- Adaptimmune Therapeutics PLC
- CIK
- CIK 1621227
- Filed
- Dec 05, 2024
- Reporting period
- Nov 30, 2024
- Description
- Schedule 13G beneficial ownership